A medical innovation that has significantly advanced medical treatments, magnetic resonance imaging has helped doctors see ...

DALLAS, July 3 /PRNewswire/ -- The U. S. Food and Drug Administration recently warned that a commonly used contrast agent used to improve MRI images has been linked to a potentially fatal disease.

An estimated 40 of every 10,000 women had an MRI at any point in pregnancy, with 12 per 10,000 for first-trimester MRI and 3 per 10,000 for gadolinium MRI.

Sometimes MRI's are done with an IV contrast agent called gadolinium to better show some structures. The study also included women who had gadolinium MRI scans at any point during pregnancy.

Analysis of MRI contrast agents Engineers dig deep to detail magnetic mechanism of gadolinium-based agents Date: November 17, 2022 Source: Rice University Summary: Simulations reveal details about ...

The Food and Drug Administration (FDA) is investigating the safety risk associated with repeated use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI).

The overall rate of MRI was 3.97 per 1,000 pregnancies. The relative risk for stillbirth or neonatal death was 1.68 (95% confidence interval [CI], 0.97 - 2.90) in mothers receiving MRI.

Gadolinium contrast agents, which are mainly administered via intravenous injection, exhibit excellent in vitro and in vivo stability. These agents have a half-life of about two hours.

While iron-based contrast agents are frequently employed for T2 scans, there are few clinically available alternatives to gadolinium for T1 tests. "Iron chelates aren't new," Halas said.

The 17 girls and 17 boys, with a mean age of 7 years, received five to 15 half-dose injections (0.05 mmol/kg body weight) during MRI over a period of 9 months to 7 years.

Gadolinium may be a useful tool to incorporate during a cardiovascular MRI, according to a recent presentation. Sangeeta B. Shah, MD, director of cardiovascular MRI at Ochsner Medical Center in ...